Citadel Advisors
SPRO icon

Citadel Advisors’s Spero Therapeutics SPRO Stock Holding History

Citadel Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.6K Sell
22,500
-50,600
-69% -$120K ﹤0.01% 12385
2025
Q4 		$170K Buy
73,100
+18,300
+33% +$42.5K ﹤0.01% 11185
2025
Q3 		$103K Sell
54,800
-82,400
-60% -$181K ﹤0.01% 11835
2025
Q2 		$398K Buy
137,200
+137,100
+137,100% +$197K ﹤0.01% 9158
2025
Q1 		$72 Sell
100
-100
-50% -$84 ﹤0.01% 14339
2024
Q4 		$206 Hold
200
– – ﹤0.01% 14367
2024
Q3 		$268 Sell
200
-800
-80% -$1.07K ﹤0.01% 14063
2024
Q2 		$1.3K Buy
+1,000
New +$1.51K ﹤0.01% 13837
2023
Q3 		– Sell
-600
Closed -$870 – 15064
2023
Q2 		$870 Buy
+600
New +$1.03K ﹤0.01% 14031
2022
Q3 		– Sell
-36,600
Closed -$27K – 13554
2022
Q2 		$27K Buy
+36,600
New +$106K ﹤0.01% 12281
2022
Q1 		– Sell
-27,400
Closed -$439K – 14514
2021
Q4 		$439K Sell
27,400
-2,000
-7% -$31.8K ﹤0.01% 10005
2021
Q3 		$541K Buy
29,400
+3,300
+13% +$53K ﹤0.01% 9673
2021
Q2 		$364K Sell
26,100
-16,200
-38% -$226K ﹤0.01% 10798
2021
Q1 		$623K Sell
42,300
-21,900
-34% -$385K ﹤0.01% 9204
2020
Q4 		$1.25M Buy
64,200
+36,500
+132% +$569K ﹤0.01% 6326
2020
Q3 		$309K Buy
+27,700
New +$328K ﹤0.01% 8082

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's SPRO Position: Q1 2026 in Review

Citadel Advisors reduced its Spero Therapeutics (SPRO) stake by 5.4% in Q1 2026, selling an estimated $50.8K and leaving 376,458 shares worth $881K. The position accounts for ﹤0.01% of the portfolio, ranked #7955.

Citadel Advisors first reported a position in SPRO in Q3 2020 and has held it in 15 quarters since. The position peaked at $927K in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Citadel Advisors held 376,458 shares of Spero Therapeutics worth $881K as of Q1 2026.
  • Citadel Advisors sold 21,406 Spero Therapeutics shares in Q1 2026, an estimated $50.8K.
  • Spero Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7955 holding.
  • Citadel Advisors first reported a position in Spero Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Citadel Advisors's Spero Therapeutics position peaked at $927K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.